NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Overview
OSL:NYKD - NO0010714785 - Common Stock
NYKD.OL Key Statistics, Chart & Performance
The current stock price of NYKD.OL is 1.54 NOK. In the past month the price decreased by -11.6%. In the past year, price decreased by -76.09%.
NYKD.OL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 19.76 | 316.57B | ||
| AMG.DE | AMGEN INC | 13.12 | 131.93B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.52 | 119.42B | ||
| 1VRTX.MI | VERTEX PHARMACEUTICALS INC | N/A | 86.48B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 23.09 | 85.89B | ||
| ARGX.BR | ARGENX SE | 81.62 | 36.96B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.70B | ||
| 1BIIB.MI | BIOGEN INC | 8.75 | 17.58B | ||
| IDP.DE | BIOGEN INC | 8.28 | 16.64B | ||
| 1EXEL.MI | EXELIXIS INC | 17.49 | 8.85B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.13B | ||
| 0QF.DE | MODERNA INC | N/A | 7.95B |
Related stock screener links
About NYKD.OL
Company Profile
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 75 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Company Info
NYKODE THERAPEUTICS ASA
Oslo Science Park, Gaustadalleen 21
Oslo OSLO NO
Employees: 75
Phone: 4722958193
NYKODE THERAPEUTICS ASA / NYKD.OL FAQ
What is the stock price of NYKODE THERAPEUTICS ASA today?
The current stock price of NYKD.OL is 1.54 NOK. The price increased by 1.18% in the last trading session.
What is the ticker symbol for NYKODE THERAPEUTICS ASA stock?
The exchange symbol of NYKODE THERAPEUTICS ASA is NYKD and it is listed on the Euronext Oslo exchange.
On which exchange is NYKD.OL stock listed?
NYKD.OL stock is listed on the Euronext Oslo exchange.
What is the price forecast or stock price prediction for NYKODE THERAPEUTICS ASA stock?
8 analysts have analysed NYKD.OL and the average price target is 5.2 NOK. This implies a price increase of 237.79% is expected in the next year compared to the current price of 1.54. Check the NYKODE THERAPEUTICS ASA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NYKODE THERAPEUTICS ASA worth?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a market capitalization of 502.89M NOK. This makes NYKD.OL a Small Cap stock.
How many employees does NYKODE THERAPEUTICS ASA have?
NYKODE THERAPEUTICS ASA (NYKD.OL) currently has 75 employees.
What are the support and resistance levels for NYKODE THERAPEUTICS ASA (NYKD.OL) stock?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a resistance level at 1.73. Check the full technical report for a detailed analysis of NYKD.OL support and resistance levels.
Is NYKODE THERAPEUTICS ASA (NYKD.OL) expected to grow?
The Revenue of NYKODE THERAPEUTICS ASA (NYKD.OL) is expected to decline by -86.43% in the next year. Check the estimates tab for more information on the NYKD.OL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NYKODE THERAPEUTICS ASA (NYKD.OL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NYKD.OL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NYKD.OL, evaluating the profitability, health, valuation and growth aspects
- NYKODE THERAPEUTICS ASA (NYKD.OL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NYKODE THERAPEUTICS ASA (NYKD.OL) Sales and EPS estimates to see what analysts future expectations are.
- NYKODE THERAPEUTICS ASA (NYKD.OL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NYKODE THERAPEUTICS ASA (NYKD.OL) Insider and Institutional Ownership to learn about the owners and their transactions.
- NYKODE THERAPEUTICS ASA (NYKD.OL) Stock Chart to make your own analysis
- NYKODE THERAPEUTICS ASA (NYKD.OL) Latest news and press-releases to stay up to date.
Does NYKODE THERAPEUTICS ASA (NYKD.OL) stock pay dividends?
NYKODE THERAPEUTICS ASA (NYKD.OL) has a dividend yield of 57.08%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of NYKD.OL dividend history, reliability and sustainability.
When does NYKODE THERAPEUTICS ASA (NYKD.OL) report earnings?
NYKODE THERAPEUTICS ASA (NYKD.OL) will report earnings on 2025-11-26.
What is the Price/Earnings (PE) ratio of NYKODE THERAPEUTICS ASA (NYKD.OL)?
NYKODE THERAPEUTICS ASA (NYKD.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
NYKD.OL Technical Analysis
NYKD.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NYKD.OL. The financial health of NYKD.OL is average, but there are quite some concerns on its profitability.
NYKD.OL Financial Highlights
Over the last trailing twelve months NYKD.OL reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 90.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.27% | ||
| ROE | -18.9% | ||
| Debt/Equity | 0.02 |
NYKD.OL Forecast & Estimates
8 analysts have analysed NYKD.OL and the average price target is 5.2 NOK. This implies a price increase of 237.79% is expected in the next year compared to the current price of 1.54.
For the next year, analysts expect an EPS growth of 40.48% and a revenue growth -86.43% for NYKD.OL